Catabasis Pharmaceuticals Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Catabasis Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Catabasis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Catabasis Pharmaceuticals is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Quick Ratio | 34.99 | |
| Fifty Two Week Low | 6.31 | |
| Target High Price | 6.00 | |
| Fifty Two Week High | 47.82 | |
| Target Low Price | 5.00 |
Catabasis |
Catabasis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in Catabasis Pharmaceuticals on January 26, 2024 and sell it today you would earn a total of 100.00 from holding Catabasis Pharmaceuticals or generate -100.0% return on investment over 90 days. Catabasis Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Catabasis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Catabasis Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catabasis Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Catabasis Pharmaceuticals, and traders can use it to determine the average amount a Catabasis Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CATB |
Based on monthly moving average Catabasis Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Catabasis Pharmaceuticals by adding Catabasis Pharmaceuticals to a well-diversified portfolio.
Catabasis Pharmaceuticals Fundamentals Growth
Catabasis Stock prices reflect investors' perceptions of the future prospects and financial health of Catabasis Pharmaceuticals, and Catabasis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Catabasis Stock performance.
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 | |||
| Current Valuation | 58.17 M | |||
| Shares Outstanding | 76.95 M | |||
| Price To Earning | (1.24) X | |||
| Price To Book | 0.98 X | |||
| Price To Sales | 258.49 X | |||
| Revenue | 250 K | |||
| EBITDA | (32.38 M) | |||
| Cash And Equivalents | 139.52 M | |||
| Cash Per Share | 10.88 X | |||
| Total Debt | 713 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | (4.32) X | |||
| Cash Flow From Operations | (34.15 M) | |||
| Earnings Per Share | (9.99) X | |||
| Total Asset | 64.17 M | |||
| Retained Earnings | (229.48 M) | |||
| Current Asset | 63.55 M | |||
| Current Liabilities | 7.78 M |
Things to note about Catabasis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Catabasis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Catabasis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Catabasis Pharmaceuticals is not yet fully synchronised with the market data | |
| Catabasis Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Catabasis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 250 K. Net Loss for the year was (221.83 M) with profit before overhead, payroll, taxes, and interest of 500 K. | |
| Catabasis Pharmaceuticals currently holds about 139.52 M in cash with (34.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.88. |
- Analyzing Catabasis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Catabasis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Catabasis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Catabasis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Catabasis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Catabasis Pharmaceuticals' stock. These opinions can provide insight into Catabasis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Catabasis Stock
If you are still planning to invest in Catabasis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catabasis Pharmaceuticals' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |